<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">843732</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.843732</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Endothelial Activin Receptor-Like Kinase 1 (ALK1) Regulates Myofibroblast Emergence and Peritubular Capillary Stability in the Early Stages of Kidney Fibrosis</article-title>
<alt-title alt-title-type="left-running-head">Mart&#xed;nez-Salgado et al.</alt-title>
<alt-title alt-title-type="right-running-head">ALK1 in Capillary Homeostasis and Renal Fibrosis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mart&#xed;nez-Salgado</surname>
<given-names>Carlos</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/838322/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>S&#xe1;nchez-Juanes</surname>
<given-names>Fernando</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>L&#xf3;pez-Hern&#xe1;ndez</surname>
<given-names>Francisco J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/966028/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mu&#xf1;oz-F&#xe9;lix</surname>
<given-names>Jos&#xe9; M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/773271/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Physiology and Pharmacology</institution>, <institution>Translational Research on Renal and Cardiovascular Diseases (TRECARD)-REDINREN (ISCIII)</institution>, <institution>University of Salamanca</institution>, <addr-line>Salamanca</addr-line>, <country>Spain</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Biomedical Research of Salamanca (IBSAL)</institution>, <addr-line>Salamanca</addr-line>, <country>Spain</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Biochemistry and Molecular Biology</institution>, <institution>University of Salamanca</institution>, <addr-line>Salamanca</addr-line>, <country>Spain</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/370424/overview">Raffaele Strippoli</ext-link>, Sapienza University of Rome, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/285242/overview">Marta Ruiz-Ortega</ext-link>, Autonomous University of Madrid, Spain</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1622283/overview">Jie Qing</ext-link>, Southwest Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/171093/overview">Carmelo Bernabeu</ext-link>, Spanish National Research Council (CSIC), Spain</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Carlos Mart&#xed;nez-Salgado, <email>carlosms@usal.es</email>; Jos&#xe9; M. Mu&#xf1;oz-F&#xe9;lix, <email>jmmb@usal.es</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>843732</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>12</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>05</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Mart&#xed;nez-Salgado, S&#xe1;nchez-Juanes, L&#xf3;pez-Hern&#xe1;ndez and Mu&#xf1;oz-F&#xe9;lix.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Mart&#xed;nez-Salgado, S&#xe1;nchez-Juanes, L&#xf3;pez-Hern&#xe1;ndez and Mu&#xf1;oz-F&#xe9;lix</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Renal tubulo-interstitial fibrosis is characterized by the excessive accumulation of extracellular matrix (ECM) in the tubular interstitium during chronic kidney disease. The main source of ECM proteins are emerging and proliferating myofibroblasts. The sources of myofibroblasts in the renal tubular interstitium have been studied during decades, in which the epithelial contribution of the myofibroblast population through the epithelial-to-mesenchymal (EMT) process was assumed to be the major mechanism. However, it is now accepted that the EMT contribution is very limited and other mechanisms such as the proliferation of local resident fibroblasts or the transdifferentiation of endothelial cells seem to be more relevant. Activin receptor-like kinase 1 (ALK1) is a type I receptor which belongs to the transforming growth factor beta (TGF-<italic>&#x3b2;</italic>) superfamily, with a key role in tissue fibrosis and production of ECM by myofibroblast. Predominantly expressed in endothelial cells, ALK1 also plays an important role in angiogenesis and vessel maturation, but the relation of these processes with kidney fibrosis is not fully understood. We show that after 3&#xa0;days of unilateral ureteral obstruction (UUO), ALK1 heterozygous mice (<italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup>) display lower levels of kidney fibrosis associated to a lower number of myofibroblasts. Moreover, <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice have a lower degree of vascular rarefaction, showing improved peritubular microvasculature after UUO. All these data suggest an important role of ALK1 in regulating vascular rarefaction and emergence of myofibroblasts.</p>
</abstract>
<kwd-group>
<kwd>ALK1</kwd>
<kwd>Angiogenesis</kwd>
<kwd>peritubular capillaries</kwd>
<kwd>myofibroblasts</kwd>
<kwd>fibrosis</kwd>
<kwd>chronic kidney disease</kwd>
</kwd-group>
<contract-num rid="cn001">PI18/00996 and RETICS RD016/0009/0025 (REDINREN)</contract-num>
<contract-sponsor id="cn001">Instituto de Salud Carlos III<named-content content-type="fundref-id">10.13039/501100004587</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Consejer&#xed;a de Educaci&#xf3;n, Junta de Castilla y Le&#xf3;n<named-content content-type="fundref-id">10.13039/501100008431</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Tissue fibrosis is a common process to several chronic diseases of the liver, lungs, and kidneys, characterized by loss of tissue parenchyma (hepatocytes, pneumocytes and tubular epithelial cells, respectively), abundance of myofibroblasts, increased secretion of extracellular matrix proteins (ECM) and capillary rarefaction (<xref ref-type="bibr" rid="B69">Zeisberg and Kalluri, 2013</xref>). Specifically, in chronic kidney disease (CKD), a progressive and irreversible loss of renal function and renal tissue integrity, is associated with tubulo-interstitial fibrosis resulting from excessive deposition of ECM proteins by myofibroblasts. Different sources of myofibroblasts contribute to renal fibrosis (<xref ref-type="bibr" rid="B23">Grande and L&#xf3;pez-Novoa, 2009</xref>; <xref ref-type="bibr" rid="B48">Munoz-Felix and Martinez-Salgado, 2021</xref>). During years, the epithelial-to-mesenchymal transition (EMT) was considered the main source (<xref ref-type="bibr" rid="B58">Sato et al., 2003</xref>; <xref ref-type="bibr" rid="B68">Zeisberg et al., 2003</xref>; <xref ref-type="bibr" rid="B23">Grande and L&#xf3;pez-Novoa, 2009</xref>; <xref ref-type="bibr" rid="B22">Grande et al., 2010</xref>) (of myofibroblasts). However, it was demonstrated that the epithelial contribution to myofibroblast abundance was around 5%, and other mechanisms such as the proliferation of local resident fibroblasts, the endothelial-to-mesenchymal transition (EndMT) and other mechanisms were involved (<xref ref-type="bibr" rid="B33">LeBleu et al., 2013</xref>; <xref ref-type="bibr" rid="B24">Grande et al., 2015</xref>).</p>
<p>Loss of the renal microcirculation due to blood vessel dropout is a major feature of chronic kidney disease (CKD) which also correlates with the progression of renal injury and tissue regeneration (<xref ref-type="bibr" rid="B25">Ishii et al., 2005</xref>). The loss of peritubular capillaries (PTC) also correlates with hypoxia and the development of fibrosis (<xref ref-type="bibr" rid="B19">Goligorsky, 2010</xref>; <xref ref-type="bibr" rid="B17">Gewin, 2019</xref>). Multiple mechanisms contribute to microvascular rarefaction such as &#x201c;drive in reverse&#x201d; or anti-angiogenic reprogramming due to the induction of anti-angiogenic programs promoted by angiostatin or endostatin (<xref ref-type="bibr" rid="B19">Goligorsky, 2010</xref>). In renal fibrosis, PTC undergo rarefaction after kidney injury (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>). In an early phase, angiogenic factors are upregulated, endothelial cells proliferate and pericytes migrate away from the capillary area. Subsequently, a progression phase ensues with vascular regression, endothelial cell disfunction and apoptosis (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>).</p>
<p>Activin receptor-like kinase 1 (ALK1) is a type I receptor from the TGF-<italic>&#x3b2;</italic>1 superfamily with a documented role in regulating ECM deposition and thus tissue fibrosis in the skin (<xref ref-type="bibr" rid="B43">Morris et al., 2011</xref>), liver (<xref ref-type="bibr" rid="B4">Breitkopf-Heinlein et al., 2017</xref>; <xref ref-type="bibr" rid="B9">Desroches-Castan et al., 2019a</xref>), heart (<xref ref-type="bibr" rid="B41">Morine et al., 2017a</xref>) and kidneys (<xref ref-type="bibr" rid="B45">Mu&#xf1;oz-F&#xe9;lix et al., 2014a</xref>). We previously showed that the increased renal fibrosis associated to ALK1 heterozygosity after 15&#xa0;days of unilateral ureteral obstruction (UUO) was due to the promotion of ECM protein synthesis in myofibroblasts, the major source of fibrotic matrix (<xref ref-type="bibr" rid="B45">Mu&#xf1;oz-F&#xe9;lix et al., 2014a</xref>). ALK1 is also involved in the regulation of endothelial cell activation (<xref ref-type="bibr" rid="B30">Lamouille et al., 2002</xref>; <xref ref-type="bibr" rid="B27">Jonker, 2014</xref>), which impinges on vascular homeostatic processes. ALK1 seems to have a dual role in angiogenesis. While some studies show a pro-angiogenic role (<xref ref-type="bibr" rid="B20">Goumans et al., 2002</xref>; <xref ref-type="bibr" rid="B34">Lebrin et al., 2005</xref>), some others have demonstrated that ALK1 inhibits the activation phase of angiogenesis (<xref ref-type="bibr" rid="B30">Lamouille et al., 2002</xref>; <xref ref-type="bibr" rid="B31">Larriv&#xe9;e et al., 2012</xref>), especially when activated by its high affinity ligand bone morphogenetic protein 9 (BMP9), a quiescent factor promoting the normalization of the vasculature (<xref ref-type="bibr" rid="B7">David et al., 2007a</xref>; <xref ref-type="bibr" rid="B6">David et al., 2008</xref>; <xref ref-type="bibr" rid="B51">Ouarn&#xe9; et al., 2018</xref>; <xref ref-type="bibr" rid="B65">Viallard et al., 2020</xref>). Apart from our previous studies, it has been recently shown the protective role of ALK1 in diabetic nephropathy due to its effect in blood vessel integrity maintenance (<xref ref-type="bibr" rid="B38">Lora Gil et al., 2020</xref>; <xref ref-type="bibr" rid="B18">Gil et al., 2021</xref>). Yet, the contribution of alterations in vascular homeostasis to tissue fibrosis is not completely understood.</p>
<p>In this manuscript we aim to elucidate the role of ALK1 in renal vascular rarefaction and integrity in a fibrotic scenario produced by UUO.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Mice</title>
<p>We used ALK1 heterozygous mice to evaluate the role of ALK1 in the early changes of the ureteral obstruction. <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice were generated as previously described (<xref ref-type="bibr" rid="B50">Oh et al., 2000</xref>). Adult <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice were kept in the pathogen-free facilities for genetically modified mice of the Animal Experimentation Service, University of Salamanca. Genotype analysis was performed by PCR with DNA isolated from mouse tail biopsies and using the primers previously reported (<xref ref-type="bibr" rid="B50">Oh et al., 2000</xref>).</p>
</sec>
<sec id="s2-2">
<title>
<italic>In vivo</italic> Experimental Model of Tubulointerstitial Fibrosis</title>
<p>Unilateral ureteral obstruction (UUO) is an experimental model of renal injury, which causes tubular cell injury, inflammation and fibrosis. UUO has been used as a model for the events that take place during chronic kidney disease (<xref ref-type="bibr" rid="B63">Ucero et al., 2014</xref>).</p>
<p>UUO was performed during 3&#xa0;days, as we aim to evaluate the early changes of this experimental approach. The unilateral ureteral obstruction (UUO) was performed as previously described (<xref ref-type="bibr" rid="B57">Rodr&#xed;guez-Pe&#xf1;a et al., 2002</xref>; <xref ref-type="bibr" rid="B21">Grande et al., 2009</xref>). In brief, 8&#xa0;weeks old male mice were anesthetized with Isoflurane (Schering-Plough, Madrid, Spain). After laparatomy, we used non-reabsorbable 5-0 silk to ligate the left ureter. To generate sham operated mice (SO), we manipulated the left kidney ureter without ligation.</p>
<p>In this study, 5 mice were included in each experimental group. Animals were kept under controlled ambient conditions in a temperature controlled-room with a 12&#xa0;h light/dark cycle, and were reared on standard chow (Panlab, Barcelona, Spain) and water <italic>ad libitum</italic>. In all procedures, mice were treated in accordance with the Recommendations of the Helsinki Declaration on the Advice on Care and Use of Animals referred to in: law 14\/2 007 (3 July) on Biomedical Research, Conseil de l&#xb4;Europe (published in Official Daily N. L358/1-358/6, 18-12-1986), Government Spanish (Royal Decree 223/1 988, (14 March) and Order of 13-10-1989, and Official Bulletin of the State b. 256, pp. 31349-31362, 28-10-1990). The procedure was approved for the Bioethics committee of the University of Salamanca and Consejer&#xed;a de Agricultura y Pesca (Junta de Castilla y Le&#xf3;n).</p>
</sec>
<sec id="s2-3">
<title>Renal Tissue Preparation</title>
<p>Obstructed (O) and contralateral kidneys (NO), as well as kidneys of sham operated mice (SO), were removed 3&#xa0;days after surgery after perfusion with heparinized saline solution at 37&#xb0;C in order to eliminate red blood cells from the tissue and to avoid endogenous peroxidase signals in immunohistochemistry procedures. Next, kidneys were halved longitudinally in order to use one half for protein extraction and analysis and the other half for stainings and immunohistochemistry. Renal samples for protein extraction were frozen in liquid nitrogen and stored at &#x2212;80&#xb0;C. Renal samples for histological studies were fixed for 24&#xa0;h in formaldehyde, transferred to ethanol 70% and then embedded in paraffin.</p>
</sec>
<sec id="s2-4">
<title>Western Blot</title>
<p>Western blot was performed for protein levels analysis in mouse kidney tissue. Tissue protein extracts were homogenized in lysis buffer (150&#xa0;mmol/L NaCl, 1% Igepal CA-630, 10&#xa0;mmol/L MgCl<sub>2</sub>, 1&#xa0;mmol/L EDTA, 10% glycerol, 1&#xa0;mmol/L Na<sub>3</sub>VO<sub>4</sub>, 25&#xa0;mmol/L NaF, l&#xa0;mmol/L PMSF, 10&#xa0;mg/ml aprotinin and 10&#xa0;mg/ml leupeptin) containing 25&#xa0;mmol/L HEPES, pH 7.5 and centrifuged at 14000&#xa0;g during 20&#xa0;min at 4&#xb0;C. Supernatants were recovered and the protein concentration was quantified using Lowry Method (BioRad). Lysates (100&#xa0;&#xb5;g per lane) were loaded onto polyacrylamide gels and the proteins were transferred to PVDF membranes (Millipore, Billerica, MA, United States) by electroblotting. Next, membranes were blocked in bovine serum albumin (BSA) 3% and were incubated overnight at 4&#xb0;C with the following antibodies: rabbit anti-collagen type I (dilution 1:1,000) and rabbit anti-fibronectin (1:1,000) from Chemicon International (Temecula, CA, United States); rabbit anti-ACVRL1 (ALK1) (1:1,000) from Abgent (Derio, Spain); mouse anti-<italic>&#x3b1;</italic>-SMA (1:5,000) from Sigma-Aldrich (Madrid, Spain); mouse anti-PCNA (1:1,000) from Transduction Laboratories (Madrid, Spain); and mouse anti-GAPDH (1:40000) from Ambion (Barcelona, Spain). After overnight incubation with the primary antibodies, membranes were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies during 60&#xa0;min (1:10000) and were developed using ECL chemiluminescence reagent (Amersham Biosciences, Barcelona, Spain). Developed signals were recorded on X-ray films (Fujifilm Spain, Barcelona, Spain) for densitometric analysis (Scion Image software, Frederick, MD, United States). GAPDH (Ambion, Barcelona, Spain) was used as loading control. GAPDH was incubated in the same membrane that the protein of interest when it was possible.</p>
</sec>
<sec id="s2-5">
<title>Histochemistry and Immunohistochemistry</title>
<p>3&#xa0;&#xb5;m sections were cut from paraffin-embedded samples and stained with haematoxylin-eosin, picrosirius, and Masson&#x2019;s trichrome. Sirius red staining was evaluated by a quantitative scoring system, Fiji (<ext-link ext-link-type="uri" xlink:href="https://imagej.net/software/fiji/">https://imagej.net/software/fiji/</ext-link>), released as open source under the GNU General Public License in 12 randomly selected fields (200X) per experimental group.</p>
<p>Immunohistochemistry was performed on buffered formalin-fixed, paraffin-embedded tissues as previously described (<xref ref-type="bibr" rid="B57">Rodr&#xed;guez-Pe&#xf1;a et al., 2002</xref>; <xref ref-type="bibr" rid="B22">Grande et al., 2010</xref>) Briefly, 3&#xa0;&#xb5;m sections were deparaffinized in xylene and rehydrated in graded ethanols (100, 80, 70 and 50%) before antigen retrieval with sodium citrate buffer pH &#x3d; 6.0, Then, primary antibodies were incubated overninght. Primary antibodies were: mouse anti-alpha smooth muscle actin (<italic>&#x3b1;</italic>-SMA, dilution 1:100, from Sigma-Aldrich), CD31 (Abcam) and rabbit anti-S100A4 (1:100 from Chemicon International, Temecula, CA, United States), mouse anti-VEGF (1:100 from Santa Cruz Biotechnology. After that staining continued with the peroxidase-antiperoxidase method. Tissue sections were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies during 60&#xa0;min (1:250). After three washes in phosphate-buffered saline (PBS: 0.81% NaCl, 2.6&#xa0;mM H<sub>2</sub>KPO<sub>4</sub>, 4.1&#xa0;mM HNa<sub>2</sub>PO<sub>4</sub>), sections were sequentially incubated with the Novolink Polymer Detection System (Novocastra, Newcastle, United Kingdom) using 3,3&#x2032;-diaminobenzidine (Biogenez, San Ram&#xf3;n CA, United States) as chromogen. Sections were counterstained with haematoxylin and were dehydrated and cover slipped. Endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide. For an adequate optimization of the method, negative controls were prepared without primary antibodies. VEGF staining was evaluated using Fiji as mentioned above in 10&#x2013;15 randomly selected fields (400X) per experimental group.</p>
</sec>
<sec id="s2-6">
<title>Immunofluorescence Staining</title>
<p>Paraffin-embedded tissues were cut in 3&#xa0;&#xb5;m sections. Heat-induced antigen retrieval was performed in sodium citrate buffer pH 6.00 in a microwave owen, and washed with PBS. Sections were incubated with endomucin (Santa Cruz Biotechnology) in combination or not with anti-<italic>&#x3b1;</italic>-SMA (Sigma Aldrich) overnight at 4&#xb0;. Following three washes in PBS, sections were incubated with anti-rat 488 Alexa and anti-mouse 546 (Molecular Probes, Barcelona, Spain), diluted 1:200 for 60&#xa0;min at room temperature, washed in PBS, and stained with 2&#xa0;&#xb5;M Hoechst 33258 (Molecular Probes, Barcelona, Spain). Slides were rinsed in PBS and mounted in Prolong anti-fade (Invitrogen, Barcelona, Spain). Confocal images were photographed using a Zeiss Axiovert 200&#xa0;M microscope and a Zeiss LSM 510 confocal module. All images were obtained with identical parameters for intensity, pinhole aperture, etc. Image manipulation of immunofluorescence analysis was performed using the same settings in all the samples and pictures shown in this manuscript, and following the image manipulation guidelines from the journal.</p>
</sec>
<sec id="s2-7">
<title>Blood Vessel Density Analysis</title>
<p>Abundance of peritubular capillaries was assessed by counting the number of CD31 or endomucin-positive microvessels in peritubular areas in the kidney cortex across 5 different fields per kidney. Glomerular capillaries were not considered for the analysis.</p>
</sec>
<sec id="s2-8">
<title>Vascular Rarefaction and Endothelial-Myofibroblast Transition Analysis</title>
<p>Apart from the blood vessel density analysis, vascular rarefaction was assessed by the individual quantitation of endomucin&#x2b; endothelial cells across 5 different fields per kidney (SO and O kidneys form <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice). Myofibroblast emergence was also assessed by the individual number of <italic>&#x3b1;</italic>-SMA&#x2b; cells excluding vascular smooth muscle cells. Hoechst counterstaining helped us to identify individual cells. Endothelial-myofibroblast transition was assessed by counting the double endomucin&#x2b; and &#x3b1;-smooth muscle actin <italic>&#x3b1;</italic>-SMA&#x2b; cells versus total endomucin &#x2b; cells across 5 fields per kidney.</p>
</sec>
<sec id="s2-9">
<title>Statistical Analysis</title>
<p>Data are expressed as mean &#xb1; standard error of the mean (SEM). The Kolmogorov-Smirnov test was used to assess the normality of the data distribution. Comparison of means was performed by two way analysis of variance (ANOVA) with Tukey&#x2019;s HSC post hoc test. Data was analyzed using Graph Pad Prism software 9.0. A &#x201c;p&#x201d; value lower than 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Renal Injury and Kidney Fibrosis After 3&#xa0;days UUO in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> Mice</title>
<p>O kidneys from both <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice show the histological events that take place after the UUO: Tubular cell injury, tubular dilation, inflammation; as shown with the Haematoxylin-eosin staining (<xref ref-type="fig" rid="F1">Figure 1A</xref>) and tubule-interstitial fibrosis, as shown with the Masson&#x2019;s trichrome staining (<xref ref-type="fig" rid="F1">Figure 1B</xref>). While we observed no differences in kidney injury between both genotypes, we detected lower tubule-interstitial fibrosis in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>UUO modifies the renal ultrastructure after 3&#xa0;days in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. <bold>(A)</bold> Haematoxylin-eosin staining in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice show the typical features of the early stages of UUO such as tubular dilatation (asterisk), interstitial cell proliferation (arrow) or immune cell infiltration (arrowhead), being these features similar in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. <bold>(B)</bold> Masson&#x2019;s trichrome staining in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice showing lower ECM deposition (asterisk) in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup>
<italic>.</italic> Scale bar &#x3d; 200 microns in both panels.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>
<italic>Alk1</italic>
<sup>&#x2b;/&#x2212;</sup>Mice Show Decreased Tubulo-Interstitial Fibrosis After 3&#xa0;days of Unilateral Ureteral Obstruction (UUO)</title>
<p>One of the most representative features of obstructive nephropathy is the accumulation of ECM proteins in the tubular interstitium, such as collagens (collagen I or collagen III), fibronectin or laminin. After our analysis of the picrosirius red staining, we observed increased levels of collagens in O kidneys form <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice but not in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice show lower kidney fibrosis after 3&#xa0;days UUO. Sirius red staining in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice (<italic>N</italic> &#x3d; 5) (upper panel). Analysis of tubule-interstitial fibrosis area in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>&#x2b;/&#x2b;</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice, assessed by Fiji (ImageJ) software. &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 (Two-way ANOVA); N.S &#x3d; Not statistically significant. Scale bar &#x3d; 250 microns.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g002.tif"/>
</fig>
<p>There is also an increase in the expression of ECM proteins (collagen I, fibronectin) in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> but not in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice evaluated by western blot (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Obstructed kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice show reduced ECM protein levels after 3&#xa0;days UUO. Western blot analysis of collagen I and fibronectin protein expression in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice, and quantification of the corresponding densitometry. Bars represent the ratio between the proteins and GAPDH, used as loading control. &#x2a;<italic>p</italic> &#x3c; 0.05; &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; N.S &#x3d; Not statistically significant (Two-way ANOVA). One statistical outlier was removed from the analysis of fibronectin in a SO mice from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Reduced Renal Myofibroblast Emergence and Proliferation in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> Mice</title>
<p>Renal myofibroblasts emerge and proliferate in the first steps of obstructive nephropathy. After 3&#xa0;days of UUO we observe an increase in the presence of myofibroblasts in the tubular initerstitium of <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice, evaluated by immunostaining of the myofibroblast markers <italic>&#x3b1;</italic>-smooth muscle actin (<italic>&#x3b1;</italic>-SMA) (<xref ref-type="fig" rid="F4">Figure 4A</xref>) and FSP1/S100A4 (<xref ref-type="fig" rid="F4">Figure 4C</xref>) and by <italic>&#x3b1;</italic>-SMA western blot analysis (<xref ref-type="fig" rid="F4">Figure 4B</xref>) in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice. However, we barely observe those increases in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>). As <italic>&#x3b1;</italic>-SMA is not only a specific maker for myofibroblasts, because it is highly expressed in vascular smooth muscle cells (VSMCs) we quantified the <italic>&#x3b1;</italic>-SMA&#x2b; individual cells by immunofluorescence with Hoechst counterstaining excluding VSMCs, and we show that O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice show a higher number of <italic>&#x3b1;</italic>-SMA&#x2b; myofibroblasts than O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice (<xref ref-type="fig" rid="F5">Figure 5</xref>). In O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice the presence of <italic>&#x3b1;</italic>-SMA positive cells is reduced and correlates with the lower ECM deposition observed in these animals. Moreover, the increase in cell proliferation is lower in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice, assessed by proliferating cell nuclear antigen (PCNA) expression (<xref ref-type="fig" rid="F4">Figure 4D</xref>). Taken all these together, we can suggest that ALK1 heterozygosity leads to a lower kidney fibrosis due to a reduced abundance and proliferation of myofibroblasts.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Reduced myofibroblast abundance and proliferation in obstructed kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice after 3&#xa0;days UUO. <bold>(A)</bold> <italic>&#x3b1;</italic>-SMA immunostaining in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. <bold>(B)</bold> Western blot analysis of <italic>&#x3b1;</italic>-SMA protein expression in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice and quantification of the corresponding densitometry analysis (<italic>N</italic> &#x3d; 5). Bars represent the ratio between <italic>&#x3b1;</italic>-SMA and GAPDH, used as loading control. <bold>(C)</bold> FSP1/S100A4 immunostaining in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. <bold>(D)</bold> Western blot analysis of PCNA protein expression in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice and quantification of the corresponding densitometry analysis. Bars represent the ratio between PCNA and GAPDH, used as loading control. &#x2a;<italic>p</italic> &#x3c; 0.05; &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; N.S &#x3d; Not statistically significant (Two-way ANOVA). The loading control for PCNA is the same as that used in <xref ref-type="fig" rid="F3">Figure 3</xref>, as both Collagen I and PCNA were incubated in the same membrane. Arrows in <bold>(A)</bold> identify VSMCs. Arrowheads in <bold>(A)</bold> and <bold>(B)</bold> identify tubulo-interstitial myofibroblasts. Scale bar &#x3d; 100 microns in A, 150 microns in <bold>(C)</bold>.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Analysis of <italic>&#x3b1;</italic>-SMA &#x2b; myofibroblasts. Identification of <italic>&#x3b1;</italic>-SMA&#x2b; myofibroblasts by immunofluorescence of <italic>&#x3b1;</italic>-SMA with Hoechst counterstaining in SO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. Squares identify zoomed areas &#x2a;<italic>p</italic> &#x3c; 0.05; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; N.S &#x3d; Not statistically significant. (Two-way ANOVA). Cropped areas identify <italic>&#x3b1;</italic>-SMA&#x2b; VSMCs from small vessels. Arrowheads identify <italic>&#x3b1;</italic>-SMA&#x2b; tubulo-interstitial myofibroblasts. Scale bar &#x3d; 150 microns.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g005.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>ALK1 Deficiency Ameliorates the Microvascular Damage Early Produced by UUO</title>
<p>As mentioned before, microvascular rarefaction is a feature of tubule-interstitial fibrosis and it contributes to the progression of hypoxia and tissue fibrosis. In the early stages of UUO, there is a vessel regression phase in which endothelial cells undergo apoptosis and pericyte adhesion is disrupted (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>). Several studies show that ALK1 is involved in vessel maturation and quiescence (<xref ref-type="bibr" rid="B1">Akla et al., 2018</xref>; <xref ref-type="bibr" rid="B65">Viallard et al., 2020</xref>).</p>
<p>We observe a decrease in blood vessel density in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice, assessed by immunostaining of the endothelial markers CD31 (<xref ref-type="fig" rid="F6">Figure 6A</xref>) and endomucin (<xref ref-type="fig" rid="F6">Figure 6B</xref>), similar to that previously described in other studies performed in the UUO model (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>). However, blood vessel density was maintained in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice after UUO, suggesting that ALK1 heterozygosity protects from vascular rarefaction in the UUO early stages.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Impaired peritubular capillaries rarefaction in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. <bold>(A)</bold> CD31 immunostaining in SO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice and blood vessel density analysis, represented as CD31 <sup>&#x2b;</sup> vessels per field. <bold>(B)</bold> Endomucin immunofluorescence staining in SO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice and blood vessel density quantification from endomucin staining, represented as microvessels per field (upper graph) and endomucin&#x2b; cells per field (lower graph) in SO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. &#x2a;<italic>p</italic> &#x3c; 0.05; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; N.S. Not statistically significant (Two-way ANOVA). Squares in <bold>(A)</bold> indicate the zoomed areas. Scale bar &#x3d; 200 microns in both panels. Blood vessels from the glomeruli in <bold>(B)</bold> (highlighted as cropped &#x00E1;reas) were not counted.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g006.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Impaired Emergence of Myofibroblasts From Endothelial Cell Origin in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> Mice</title>
<p>As stated before, myofibroblasts in the obstructed kidney emerge from different origins such as proliferating local resident fibroblasts, bone marrow derived cells or vascular cells. Vascular endothelial cells and pericytes can transdifferentiate into myofibroblasts. To dissect the myofibroblast cells that arise from endothelial cells we have double-immunostained kidney sections with an endothelial marker (endomucin) and a myofibroblast marker (<italic>&#x3b1;</italic>-SMA). Thus, cells with double positive staining for endomucin and <italic>&#x3b1;</italic>-SMA are endothelial cells being transdifferentiated into myofibroblasts. We observed that these double stained cells are more abundant in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice than in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice (<xref ref-type="fig" rid="F7">Figure 7</xref>). This finding indicates that the lower abundance of myofibroblasts observed in ALK1 heterozygous mice is due to a lower transdifferentiation from endothelial cells and this correlates with the PTC stability after 3&#xa0;days UUO in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Endothelial-to-myofibroblast transdifferentiation after UUO in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. Double immunofluorescence of endomucin (endothelial marker) and <italic>&#x3b1;</italic>-SMA (myofibroblast marker) in SO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice and quantification of double endomucin and <italic>&#x3b1;</italic>-SMA positive cells. Cropped areas with small dashed line are glomeruli, not considered for the analysis. Cropped areas with large dashed lines are small vessels, also not considered for the analysis. &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; N.S. Not statistically significant (Two-way ANOVA). Arrows identify double endomucin&#x2b;&#x2014;<italic>&#x3b1;</italic>-SMA&#x2b; cells. Scale bar &#x3d; 200 microns.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g007.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>
<italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> Mice Are Protected From Vessel Regression After 3&#xa0;days UUO</title>
<p>ALK1 was described by David et al. (2008) as a molecule which induces quiescence and inhibits endothelial cell proliferation and migration (<xref ref-type="bibr" rid="B30">Lamouille et al., 2002</xref>; <xref ref-type="bibr" rid="B6">David et al., 2008</xref>). Angiogenesis is a process linked with the development of tubule-interstitial fibrosis after UUO. We found an increase of ALK1 expression in O kidneys from both <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice which may indicate the beginning of the regression phase of angiogenesis after obstruction. As expected, we do not observe increased levels of ALK1 receptor in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice after UUO, suggesting a pro-angiogenic effect in these animals (<xref ref-type="fig" rid="F8">Figure 8A</xref>). To elucidate the differences in the angiogenic process during vascular rarefaction after UUO, we have analyzed the levels of one of the most important angiogenic factors, vascular endothelial growth factor (VEGF). We detected no differences in VEGF expression after UUO in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice but we observed a higher expression in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice (<xref ref-type="fig" rid="F8">Figure 8B</xref>). Taken all these together, we suggest that the lower ALK1 levels and increased levels of VEGF in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice may correlate with a delay of the regression phase of angiogenesis that prevents endothelial-pericyte detachment, contributing to microvascular preservation and impaired endothelial to myofibroblast transdifferentiation.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>ALK1 and VEGF protein expression after UUO. <bold>(A)</bold> Western blot analysis of ALK1 protein in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice (<italic>N</italic> &#x3d; 5), and quantification of the corresponding densitometry analysis. Bars represent the ratio between the proteins and GAPDH, used as loading control. <bold>(B)</bold> VEGF immunohistochemistry representative pictures and quantification of VEGF levels (using Fiji software) in SO, NO and O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. &#x2a;<italic>p</italic> &#x3c; 0.05; &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 N.S. Non statistically significant (Two-way ANOVA). Scale bar &#x3d; 150 microns.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g008.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Renal myofibroblasts are the main source of ECM proteins during tubule-interstitial fibrosis (<xref ref-type="bibr" rid="B32">LeBleu and Kalluri, 2011</xref>). Myofibroblasts are activated fibroblasts with high contractile capacity, and with a high capacity to synthesize ECM proteins such as collagens, fibronectin or laminin (<xref ref-type="bibr" rid="B48">Munoz-Felix and Martinez-Salgado, 2021</xref>). These cells emerge during the first steps of the fibrotic process from different origins. Numerous studies attributed their origin to the epithelial-to-mesenchymal transition (EMT) program (<xref ref-type="bibr" rid="B23">Grande and L&#xf3;pez-Novoa, 2009</xref>). However, although the EMT process has been validated in renal cells <italic>in vitro</italic> (<xref ref-type="bibr" rid="B13">Docherty et al., 2006a</xref>), the contribution of the epithelial components to myofibroblast abundance is very limited, as it has been demonstrated <italic>in vivo</italic> (<xref ref-type="bibr" rid="B55">Picard et al., 2008</xref>; <xref ref-type="bibr" rid="B24">Grande et al., 2015</xref>). The most important origins and mechanisms of myofibroblast emergence are proliferating local resident fibroblasts and the transdifferentiation from endothelial cells or and pericytes (<xref ref-type="bibr" rid="B33">LeBleu et al., 2013</xref>).</p>
<p>In this study we observe a lower kidney fibrosis after 3&#xa0;days UUO which correlates with a lower myofibroblast abundance in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. Moreover, we show a lower microvascular rarefaction in these mice. Vascular rarefaction is involved in myofibroblast emergence by different mechanisms. In the early phases of UUO, endothelial cells undergo an apoptotic program which lead to the detachment of endothelial cells from pericytes (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>). Endothelial cells can transdifferentiate into myofibroblasts <italic>via</italic> the endothelial to mesenchymal transition program (<xref ref-type="bibr" rid="B67">Zeisberg et al., 2008</xref>). On the other hand, pericytes can migrate from the basement membrane and transdifferentiate into myofibroblasts (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>). Our data suggest that the maintenance of the microvascular architecture observed in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> may be related with the lower emergence of myofibroblasts observed in these mice and the lower ECM deposition as a possible consequence of the reduced number of myofibroblasts (<xref ref-type="fig" rid="F9">Figure 9</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Proposed cellular mechanism. After 3&#xa0;days of Unilateral Ureteral Obstruction (UUO), myofibroblasts emerge in the renal tubular interstitium and synthesize ECM proteins. At the same time, peritubular capillaries (PTC) undergo vascular rarefaction. This process starts with an angiogenic phase followed by a regression phase in which endothelial cells detach from pericytes and basement membrane, followed by apoptosis and leading to loss of functional capillaries. Both endothelial cells and pericytes can transdifferentiate into myofibroblasts and act as a source of extracellular matrix (ECM) components <bold>(A,C)</bold>. ALK1 heterozygosity is associated with PTC stability linked to an angiogenic process VEGF-dependent and the reduction of myofibroblast abundance, leading to reduced tubule-interstitial fibrosis <bold>(A,B)</bold> Previous results from our laboratory demonstrated that after 15&#xa0;days of UUO, <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice show the same number of myofibroblasts but those from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice produce higher amounts of ECM proteins leading to increased tubulointerstitial fibrosis <bold>(C,D)</bold>. Figure 9 was created using <ext-link ext-link-type="uri" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p>
</caption>
<graphic xlink:href="fphar-13-843732-g009.tif"/>
</fig>
<p>The process by which PTC undergo rarefaction comprises two different stages: Initially, there is an angiogenic phase where angiogenic factors such as VEGF are upregulated and inflammatory cell infiltration happens. Later, the vascular regression phase occurs when a decrease of angiogenic factors and an increase of anti-angiogenic factors takes place in the obstructed kidney (<xref ref-type="bibr" rid="B29">Kida et al., 2014</xref>). Endothelial cells and pericytes are detached in the regression phase and can be transdifferentiated to myofibroblasts. Our data suggest that ALK1 is regulating this phenomenon. We observed lower vascular rarefaction in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice after 3&#xa0;days of UUO. ALK1 regulates negatively the activation phase of angiogenesis (<xref ref-type="bibr" rid="B3">Ayuso-Inigo et al., 2021</xref>) and it is expected that lower levels of ALK1 in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice lead to a maintained angiogenic phase or an impaired vessel regression phase, which also correlates with the higher VEGF levels observed in O kidneys from <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice. Our observations are in concordance with those of Sharpfenecker et al. (2011), who demonstrated in a kidney fibrosis model after irradiation that <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice show lower vascular injury after 20&#xa0;weeks of irradiation, and this correlated with higher levels of VEGF and VEGFR2 at that time point (<xref ref-type="bibr" rid="B59">Scharpfenecker et al., 2011</xref>).</p>
<p>Years ago, we demonstrated a role of ALK1 in counteracting TGF-<italic>&#x3b2;</italic>1-induced kidney fibrosis at 15&#xa0;days UUO (<xref ref-type="bibr" rid="B45">Mu&#xf1;oz-F&#xe9;lix et al., 2014a</xref>). In that context, both <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> and <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2b;</italic>
</sup> mice showed same myofibroblast abundance but <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> myofibroblasts produced higher amounts of ECM proteins (<xref ref-type="bibr" rid="B47">Mu&#xf1;oz-F&#xe9;lix et al., 2014b</xref>; <xref ref-type="bibr" rid="B52">Oujo et al., 2014</xref>). In this manuscript we demonstrate that after 3&#xa0;days UUO ALK1 heterozygosity is associated with a lower myofibroblast emergence, due to a higher microvessel stability, and this lower number of myofibroblasts results in a decrease in tubulo-interstitial fibrosis. We suggest that in the early stages of UUO, ALK1 function is mainly related with its effect on endothelial cells. The different effects of ALK1 receptor in kidney fibrosis at different time points following UUO can be explained by the different cellular players in these different stages of fibrosis progression. We suggest that in the early stages of the ureteral obstruction ALK1 is regulating the myofibroblast emergence from endothelial cells while after 15&#xa0;days UUO the fibrotic program is completely established and myofibroblast number is elevated and ALK1 regulates negatively ECM protein synthesis by myofibroblasts through an inhibition of TGF-<italic>&#x3b2;</italic>1/Smad2/3 pathway (<xref ref-type="bibr" rid="B47">Mu&#xf1;oz-F&#xe9;lix et al., 2014b</xref>).</p>
<p>Although our previous studies demonstrate a role of ALK1 in regulating ECM production by ECM producing cells like fibroblasts, the biological role of ALK1 has been traditionally considered more relevant in the regulation of endothelial cell balance during development, cardiovascular diseases and tumor angiogenesis (<xref ref-type="bibr" rid="B3">Ayuso-Inigo et al., 2021</xref>). To understand ALK1 function in tissue fibrosis is very important to consider two molecular players that regulate ALK1 activity: Its high affinity ligand BMP9 (<xref ref-type="bibr" rid="B8">David et al., 2007b</xref>) and the coreceptor endoglin (<xref ref-type="bibr" rid="B35">Lebrin et al., 2004</xref>; <xref ref-type="bibr" rid="B37">L&#xf3;pez-Novoa and Bernabeu, 2010</xref>). Both molecules have been studied in depth as regulators of vascular homeostasis and tissue fibrosis (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>ALK1, BMP9 and Endoglin effects in tissue fibrosis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="4" align="left">ALK1</th>
<th colspan="4" align="center">BMP9</th>
<th colspan="4" align="center">Endoglin</th>
</tr>
<tr>
<th colspan="2" align="left">Profibrotic effect</th>
<th colspan="2" align="center">Antifibrotic effect</th>
<th colspan="2" align="center">Profibrotic effect</th>
<th colspan="2" align="center">Antifibrotic effect</th>
<th colspan="2" align="center">Profibrotic effect</th>
<th colspan="2" align="center">Antifibrotic effect</th>
</tr>
<tr>
<th align="left">Ref.</th>
<th align="center">Experimental model</th>
<th align="center">Ref.</th>
<th align="center">Experimental model</th>
<th align="center">Ref.</th>
<th align="center">Experimental model</th>
<th align="center">Ref.</th>
<th align="center">Experimental model</th>
<th align="center">Ref.</th>
<th align="center">Experimental model</th>
<th align="center">Ref.</th>
<th align="center">Experimental model</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<xref ref-type="bibr" rid="B59">Scharpfenecker et al. (2011)</xref>
</td>
<td align="left">Kidney fibrosis by irradiation in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B45">Mu&#xf1;oz-F&#xe9;lix et al. (2014a)</xref>
</td>
<td align="left">Unilateral Ureteral Obstruction (UUO) during 15&#xa0;days in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B44">Mu&#xf1;oz-F&#xe9;lix et al. (2016a)</xref>
</td>
<td align="left">Cultured mouse embryo fibroblasts</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Morine et al. (2018)</xref>
</td>
<td align="left">Transverse aortic constriction (TAC) in Bmp9-KO mice.</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Scharpfenecker et al. (2012)</xref>
</td>
<td align="left">Kidney fibrosis by irradiation in <italic>Eng</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B46">Mu&#xf1;oz-F&#xe9;lix et al. (2016b)</xref>
</td>
<td align="left">UUO in <italic>S-Eng</italic>
<sup>
<italic>&#x2b;</italic>
</sup> mice (mice overexpressing human Short endoglin).</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B40">Morine et al. (2017b)</xref>
</td>
<td align="left">Deletion of ALK1 with conditional knockout mice</td>
<td align="left">
<xref ref-type="bibr" rid="B41">Morine et al. (2017a)</xref>
</td>
<td align="left">Transverse aortic constriction (TAC) in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B36">Li et al. (2018)</xref>
</td>
<td align="left">CCl<sub>4</sub> induced liver fibrosis Bile duct ligation (BDL) induced liver fibrosis</td>
<td align="left">
<xref ref-type="bibr" rid="B9">Desroches-Castan et al. (2019a)</xref>
</td>
<td align="left">
<italic>Bmp9</italic>-KO mice</td>
<td align="left">
<xref ref-type="bibr" rid="B62">Scharpfenecker et al. (2009)</xref>
</td>
<td align="left">Kidney fibrosis by irradiation in <italic>Eng</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B54">Pericacho et al. (2013)</xref>
</td>
<td align="left">Cutured dermal fibroblasts from <italic>Eng</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B66">Wiercinska et al. (2006)</xref>
</td>
<td align="left">Cultured hepatic stellate cells</td>
<td align="left">
<xref ref-type="bibr" rid="B47">Mu&#xf1;oz-F&#xe9;lix et al. (2014b)</xref>
</td>
<td align="left">Cultured mouse embryo fibroblasts form <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B4">Breitkopf-Heinlein et al. (2017)</xref>
</td>
<td align="left">CCL<sub>4</sub> and LPS induced liver fibrosis. BMP9 inactivated with adenoviruses</td>
<td align="left">
<xref ref-type="bibr" rid="B10">Desroches-Castan et al. (2019b)</xref>
</td>
<td align="left">
<italic>Bmp9</italic>-KO mice</td>
<td align="left">
<xref ref-type="bibr" rid="B60">Scharpfenecker et al. (2013)</xref>
</td>
<td align="left">Kidney fibrosis by irradiation in <italic>Eng</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B64">Velasco et al. (2008)</xref>
</td>
<td align="left">Cultured L6E9 rat myoblasts overexpressing L-Endoglin</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B4">Breitkopf-Heinlein et al. (2017)</xref>
</td>
<td align="left">CCL<sub>4</sub> and LPS induced liver fibrosis. BMP9 inactivated with adenoviruses</td>
<td align="left">
<xref ref-type="bibr" rid="B15">Finnson et al. (2008)</xref>
</td>
<td align="left">Cultured human chondrocytes</td>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B26">Jiang et al. (2021)</xref>
</td>
<td align="left">Bleomycin-induced pulmonary fibrosis</td>
<td align="left">
<xref ref-type="bibr" rid="B12">Docherty et al. (2006b)</xref>
</td>
<td align="left">Kidney fibrosis induced by Ischaemia-reperfusion injury in <italic>Eng</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B14">Finnson et al. (2010)</xref>
</td>
<td align="left">Cultured human chondrocytes</td>
</tr>
<tr>
<td align="left">This current manuscript</td>
<td align="left">UUO during 3&#xa0;days in <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B5">Chen et al. (2017)</xref>
</td>
<td align="left">BMP9 treatment in neonatal rats</td>
<td align="left">
<xref ref-type="bibr" rid="B28">Kapur et al. (2012)</xref>
</td>
<td align="left">TAC in <italic>Eng</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice</td>
<td align="left">
<xref ref-type="bibr" rid="B2">Alzahrani et al. (2018)</xref>
</td>
<td align="left">Skin fibrosis induced by bleomycin</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B52">Oujo et al. (2014)</xref>
</td>
<td align="left">UUO in <italic>L-Eng</italic>
<sup>
<italic>&#x2b;</italic>
</sup> mice (mice overexpressing human Large endoglin).</td>
<td align="left">
<xref ref-type="bibr" rid="B49">Obreo et al. (2004)</xref>
</td>
<td align="left">Cultured L6E9 myoblasts</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B16">Gerrits et al. (2020)</xref>
</td>
<td align="left">cultured human renal myofibroblasts</td>
<td align="left">
<xref ref-type="bibr" rid="B11">Diez-Marques et al. (2002)</xref>
</td>
<td align="left">Cultured human mesangial cells</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B53">Owen et al. (2020)</xref>
</td>
<td align="left">Patients with cirrhosis</td>
<td align="left">
<xref ref-type="bibr" rid="B56">Rodr&#xed;guez-Barbero et al. (2006)</xref>
</td>
<td align="left">Cultured L6E9 myoblasts</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B43">Morris et al. (2011)</xref>
</td>
<td align="left">Cultured scleroderma (SSc) fibroblasts</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B39">Meurer et al. (2011)</xref>
</td>
<td align="left">Cultured Hepatic stellate cells</td>
<td align="left"/>
<td align="left"/>
</tr>
</tbody>
</table>
</table-wrap>
<p>However, the link of the ALK1-mediated endothelial effects and tissue fibrosis has not been studied in depth so far. Nevertheless, new functions have been recently described in different tissues such as liver and kidney. In the liver, ALK1 is involved in capillary fenestration and prevents the development of liver fibrosis (<xref ref-type="bibr" rid="B9">Desroches-Castan et al., 2019a</xref>). In this study, the authors show that mice lacking BMP9, a high affinity receptor for ALK1, show enlarged sinusoidal vessels and a reduced number of fenestrae. This suggests an interesting role of the BMP9-ALK1 axis in liver fibrosis protection. In renal tissue, a role for ALK1 in vascular cells has been described in diabetic nephropathy. ALK1 levels decrease in diabetic mice, being ALK1 expression circumscribed to glomerular capillaries. ALK1 heterozygous mice display albuminuria, as a result of changes in endothelial cells and podocytes, leading to exacerbated levels of collagen IV and thickening of the glomerular basement membrane (<xref ref-type="bibr" rid="B38">Lora Gil et al., 2020</xref>).</p>
<p>Our study shows that ALK1 is involved in the regulation of the stability of renal peritubular capillaries. In the same circumstances we observe a lower number of myofibroblasts in mice with lower expression of ALK1, which also show lower tubule-interstitial fibrosis. With these results, we suggest that both processes may be linked. Reduced levels of ALK1 together with an increase in VEGF levels maintains the stability of peritubular capillaries protecting kidney from myofibroblast emergence and ECM deposition. Considering all these facts, ALK1 seems to regulate the endothelial activation and quiescence in the context of UUO. Endothelial activation in kidney fibrosis occurs in the early steps of vascular rarefaction, and it is accompanied of endothelial and pericyte detachments. Both cell types might be the source of the increased number of myofibroblasts, as it has been demonstrated during the last years (<xref ref-type="bibr" rid="B69">Zeisberg and Kalluri, 2013</xref>).</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>ALK1 is involved in the early changes of UUO, promoting the development of vascular rarefaction. <italic>Alk1</italic>
<sup>
<italic>&#x2b;/&#x2212;</italic>
</sup> mice maintain the stability of the peritubular capillaries network after UUO, leading to a decrease of myofibroblasts emergence and ECM deposition.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by The procedure was approved for the Bioethics committee of the University of Salamanca and Consejer&#xed;a de Agricultura y Pesca (Junta de Castilla y Le&#xf3;n).</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>CM-S, FS-J, FL-H, and JM-F conceived the idea, design the experiments, carried out the experimental research, analyzed the data and wrote the manuscript.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>This work was supported by grants from Instituto de Salud Carlos III, Ministerio de Ciencia e Innovaci&#xf3;n: PI18/00996 and RETICS RD016/0009/0025 (REDINREN), co-funded by FEDER funds, and from Consejeria de Educaci&#xf3;n, Junta de Castilla y Le&#xf3;n: IES160P20 and Universidad de Salamanca (Programas Propios de la Agencia de Gesti&#xf3;n de la Investigaci&#xf3;n).</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We thank Annette D&#xfc;wel and Luc&#xed;a Mart&#xed;n for their technical assistance, especially in genotyping the animals. <xref ref-type="fig" rid="F9">Figure 9</xref> was created using <ext-link ext-link-type="uri" xlink:href="BioRender.com">BioRender.com</ext-link>, with the agreement number JJ23WW3A8X (License granted to JM-F).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akla</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Viallard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Popovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lora Gil</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sapieha</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Larriv&#xe9;e</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source> <volume>38</volume>, <fpage>1821</fpage>&#x2013;<lpage>1836</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.310733</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alzahrani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Finnson</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Blati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lussier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Endoglin Haploinsufficiency Is Associated with Differential Regulation of Extracellular Matrix Production during Skin Fibrosis and Cartilage Repair in Mice</article-title>. <source>J. Cell Commun. Signal</source> <volume>12</volume>, <fpage>379</fpage>&#x2013;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1007/s12079-018-0461-7</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayuso-Inigo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mendez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pericacho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Munoz-Felix</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?</article-title> <source>Cancers (Basel)</source> <volume>13</volume>. <fpage>5412</fpage>, <pub-id pub-id-type="doi">10.3390/cancers13215412</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breitkopf-Heinlein</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>K&#xf6;nig</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gaitantzi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Addante</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>BMP-9 Interferes with Liver Regeneration and Promotes Liver Fibrosis</article-title>. <source>Gut</source> <volume>66</volume>, <fpage>939</fpage>&#x2013;<lpage>954</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2016-313314</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Orriols</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Laghmani</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Hoogeboom</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Hogen-Esch</surname>
<given-names>A. C. B.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Bone Morphogenetic Protein 9 Protects against Neonatal Hyperoxia-Induced Impairment of Alveolarization and Pulmonary Inflammation</article-title>. <source>Front. Physiol.</source> <volume>8</volume>, <fpage>486</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.00486</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Keramidas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lamand&#xe9;</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gasc</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Dupuis-Girod</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor</article-title>. <source>Circ. Res.</source> <volume>102</volume>, <fpage>914</fpage>&#x2013;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.165530</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mazerbourg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Feige</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Bailly</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Identification of BMP9 and BMP10 as Functional Activators of the Orphan Activin Receptor-like Kinase 1 (ALK1) in Endothelial Cells</article-title>. <source>Blood</source> <volume>109</volume>, <fpage>1953</fpage>&#x2013;<lpage>1961</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2006-07-034124</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vailh&#xe9;</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lamouille</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Feige</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Bailly</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Activin Receptor-like Kinase 1 Inhibits Human Microvascular Endothelial Cell Migration: Potential Roles for JNK and ERK</article-title>. <source>J. Cell Physiol.</source> <volume>213</volume>, <fpage>484</fpage>&#x2013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.21126</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desroches-Castan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tillet</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ricard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ouarn&#xe9;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Belmudes</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Bone Morphogenetic Protein 9 Is a Paracrine Factor Controlling Liver Sinusoidal Endothelial Cell Fenestration and Protecting against Hepatic Fibrosis</article-title>. <source>Hepatology</source> <volume>70</volume>, <fpage>1392</fpage>&#x2013;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1002/hep.30655</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desroches-Castan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tillet</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ricard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ouarn&#xe9;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Feige</surname>
<given-names>J. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Differential Consequences of Bmp9 Deletion on Sinusoidal Endothelial Cell Differentiation and Liver Fibrosis in 129/Ola and C57BL/6 Mice</article-title>. <source>Cells</source> <volume>8</volume>. <fpage>1079</fpage>, <pub-id pub-id-type="doi">10.3390/cells8091079</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diez-Marques</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ortega-Velazquez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Langa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rodriguez-Barbero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lopez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Lamas</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Expression of Endoglin in Human Mesangial Cells: Modulation of Extracellular Matrix Synthesis</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1587</volume>, <fpage>36</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/s0925-4439(02)00051-0</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Docherty</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Arevalo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D&#xfc;wel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rodriguez-Pe&#xf1;a</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Barriocanal</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Endoglin Regulates Renal Ischaemia-Reperfusion Injury</article-title>. <source>Nephrol. Dial. Transpl.</source> <volume>21</volume>, <fpage>2106</fpage>&#x2013;<lpage>2119</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfl179</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Docherty</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>O&#x27;Sullivan</surname>
<given-names>O. E.</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>O&#x27;neill</surname>
<given-names>A. J. A.</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>TGF-beta1-induced EMT Can Occur Independently of its Proapoptotic Effects and Is Aided by EGF Receptor Activation</article-title>. <source>Am. J. Physiol. Ren. Physiol.</source> <volume>290</volume>, <fpage>F1202</fpage>&#x2013;<lpage>F1212</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00406.2005</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finnson</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hoemann</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Goldring</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Antoniou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Endoglin Differentially Regulates TGF-<italic>&#x3b2;</italic>-Induced Smad2/3 and Smad1/5 Signalling and its Expression Correlates with Extracellular Matrix Production and Cellular Differentiation State in Human Chondrocytes</article-title>. <source>Osteoarthr. Cartil.</source> <volume>18</volume>, <fpage>1518</fpage>&#x2013;<lpage>1527</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2010.09.002</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finnson</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>ten Dijke</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thorikay</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Philip</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>ALK1 Opposes ALK5/Smad3 Signaling and Expression of Extracellular Matrix Components in Human Chondrocytes</article-title>. <source>J. Bone Min. Res.</source> <volume>23</volume>, <fpage>896</fpage>&#x2013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1359/jbmr.080209</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerrits</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zandbergen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wolterbeek</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bruijn</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Baelde</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Scharpfenecker</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Endoglin Promotes Myofibroblast Differentiation and Extracellular Matrix Production in Diabetic Nephropathy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>. <fpage>7713</fpage>, <pub-id pub-id-type="doi">10.3390/ijms21207713</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gewin</surname>
<given-names>L. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Transforming Growth Factor-<italic>&#x3b2;</italic> in the Acute Kidney Injury to Chronic Kidney Disease Transition</article-title>. <source>Nephron</source> <volume>143</volume>, <fpage>154</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1159/000500093</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Hooker</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Larriv&#xe9;e</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Diabetic Kidney Disease, Endothelial Damage, and Podocyte-Endothelial Crosstalk</article-title>. <source>Kidney Med.</source> <volume>3</volume>, <fpage>105</fpage>&#x2013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.xkme.2020.10.005</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goligorsky</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Microvascular Rarefaction: the Decline and Fall of Blood Vessels</article-title>. <source>Organogenesis</source> <volume>6</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.4161/org.6.1.10427</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goumans</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Valdimarsdottir</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rosendahl</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sideras</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>ten Dijke</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Balancing the Activation State of the Endothelium via Two Distinct TGF-Beta Type I Receptors</article-title>. <source>EMBO J.</source> <volume>21</volume>, <fpage>1743</fpage>&#x2013;<lpage>1753</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/21.7.1743</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grande</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Ar&#xe9;valo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cannata-And&#xed;a</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Targeted Genomic Disruption of H-Ras and N-Ras Has No Effect on Early Renal Changes after Unilateral Ureteral Ligation</article-title>. <source>World J. Urol.</source> <volume>27</volume>, <fpage>787</fpage>&#x2013;<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-009-0399-8</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grande</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Fuentes-Calvo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ar&#xe9;valo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heredia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Salgado</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Deletion of H-Ras Decreases Renal Fibrosis and Myofibroblast Activation Following Ureteral Obstruction in Mice</article-title>. <source>Kidney Int.</source> <volume>77</volume>, <fpage>509</fpage>&#x2013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2009.498</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grande</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Fibroblast Activation and Myofibroblast Generation in Obstructive Nephropathy</article-title>. <source>Nat. Rev. Nephrol.</source> <volume>5</volume>, <fpage>319</fpage>&#x2013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2009.74</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grande</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Laorden</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Blau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Frutos</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Boutet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ar&#xe9;valo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Snail1-induced Partial Epithelial-To-Mesenchymal Transition Drives Renal Fibrosis in Mice and Can Be Targeted to Reverse Established Disease</article-title>. <source>Nat. Med.</source> <volume>21</volume>, <fpage>989</fpage>&#x2013;<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3901</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishii</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fuchinoue</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Teraoka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Injury and Progressive Loss of Peritubular Capillaries in the Development of Chronic Allograft Nephropathy</article-title>. <source>Kidney Int.</source> <volume>67</volume>, <fpage>321</fpage>&#x2013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00085.x</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Dysregulation of BMP9/BMPR2/SMAD Signalling Pathway Contributes to Pulmonary Fibrosis and Pulmonary Hypertension Induced by Bleomycin in Rats</article-title>. <source>Br. J. Pharmacol.</source> <volume>178</volume>, <fpage>203</fpage>&#x2013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15285</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jonker</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>TGF-<italic>&#x3b2;</italic> &#x26; BMP Receptors Endoglin and ALK1: Overview of Their Functional Role and Status as Antiangiogenic Targets</article-title>. <source>Microcirculation</source> <volume>21</volume>, <fpage>93</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1111/micc.12099</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapur</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yunis</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mackey</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Paruchuri</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure</article-title>. <source>Circulation</source> <volume>125</volume>, <fpage>2728</fpage>&#x2013;<lpage>2738</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.080002</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tchao</surname>
<given-names>B. N.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Peritubular Capillary Rarefaction: a New Therapeutic Target in Chronic Kidney Disease</article-title>. <source>Pediatr. Nephrol.</source> <volume>29</volume>, <fpage>333</fpage>&#x2013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1007/s00467-013-2430-y</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamouille</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Feige</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Bailly</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Activin Receptor-like Kinase 1 Is Implicated in the Maturation Phase of Angiogenesis</article-title>. <source>Blood</source> <volume>100</volume>, <fpage>4495</fpage>&#x2013;<lpage>4501</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V100.13.4495</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larriv&#xe9;e</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prahst</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>del Toro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mathivet</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway</article-title>. <source>Dev. Cell</source> <volume>22</volume>, <fpage>489</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2012.02.005</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeBleu</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Kalluri</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Blockade of PDGF Receptor Signaling Reduces Myofibroblast Number and Attenuates Renal Fibrosis</article-title>. <source>Kidney Int.</source> <volume>80</volume>, <fpage>1119</fpage>&#x2013;<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2011.300</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeBleu</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Taduri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>O&#x27;Connell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>V. G.</given-names>
</name>
<name>
<surname>Woda</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Origin and Function of Myofibroblasts in Kidney Fibrosis</article-title>. <source>Nat. Med.</source> <volume>19</volume>, <fpage>1047</fpage>&#x2013;<lpage>1053</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3218</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lebrin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Deckers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bertolino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ten Dijke</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>TGF-beta Receptor Function in the Endothelium</article-title>. <source>Cardiovasc Res.</source> <volume>65</volume>, <fpage>599</fpage>&#x2013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1016/j.cardiores.2004.10.036</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lebrin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Goumans</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Jonker</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Valdimarsdottir</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thorikay</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Endoglin Promotes Endothelial Cell Proliferation and TGF-beta/ALK1 Signal Transduction</article-title>. <source>EMBO J.</source> <volume>23</volume>, <fpage>4018</fpage>&#x2013;<lpage>4028</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7600386</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Targeting Secreted Cytokine BMP9 Gates the Attenuation of Hepatic Fibrosis</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source> <volume>1864</volume>, <fpage>709</fpage>&#x2013;<lpage>720</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2017.12.008</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Bernabeu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The Physiological Role of Endoglin in the Cardiovascular System</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>299</volume>, <fpage>H959</fpage>&#x2013;<lpage>H974</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.01251.2009</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lora Gil</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Henley</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leblond</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Akla</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Laurin</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Royal</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Alk1 Haploinsufficiency Causes Glomerular Dysfunction and Microalbuminuria in Diabetic Mice</article-title>. <source>Sci. Rep.</source> <volume>10</volume>, <fpage>13136</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-68515-z</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meurer</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Tihaa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Borkham-Kamphorst</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weiskirchen</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Expression and Functional Analysis of Endoglin in Isolated Liver Cells and its Involvement in Fibrogenic Smad Signalling</article-title>. <source>Cell Signal</source> <volume>23</volume>, <fpage>683</fpage>&#x2013;<lpage>699</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2010.12.002</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morine</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Paruchuri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Aronovitz</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Mackey</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Buiten</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Conditional Knockout of Activin like Kinase-1 (ALK-1) Leads to Heart Failure without Maladaptive Remodeling</article-title>. <source>Heart Vessels</source> <volume>32</volume>, <fpage>628</fpage>&#x2013;<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1007/s00380-017-0955-x</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morine</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Paruchuri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Aronovitz</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Mackey</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Buiten</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Reduced Activin Receptor-like Kinase 1 Activity Promotes Cardiac Fibrosis in Heart Failure</article-title>. <source>Cardiovasc Pathol.</source> <volume>31</volume>, <fpage>26</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.carpath.2017.07.004</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morine</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Natov</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Paruchuri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure</article-title>. <source>Circulation</source> <volume>138</volume>, <fpage>513</fpage>&#x2013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031635</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chrobak</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bujor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hant</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ten Dijke</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Endoglin Promotes TGF-&#x3b2;/Smad1 Signaling in Scleroderma Fibroblasts</article-title>. <source>J. Cell Physiol.</source> <volume>226</volume>, <fpage>3340</fpage>&#x2013;<lpage>3348</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.22690</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz-F&#xe9;lix</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Cuesta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Perretta-Tejedor</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Subileau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Hern&#xe1;ndez</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Identification of Bone Morphogenetic Protein 9 (BMP9) as a Novel Profibrotic Factor <italic>In Vitro</italic>
</article-title>. <source>Cell Signal</source> <volume>28</volume>, <fpage>1252</fpage>&#x2013;<lpage>1261</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2016.05.015</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz-F&#xe9;lix</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Salgado</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Heterozygous Disruption of Activin Receptor-like Kinase 1 Is Associated with Increased Renal Fibrosis in a Mouse Model of Obstructive Nephropathy</article-title>. <source>Kidney Int.</source> <volume>85</volume>, <fpage>319</fpage>&#x2013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2013.292</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz-F&#xe9;lix</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Roque</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez-G&#xf3;mez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Oujo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ar&#xe9;valo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ruiz-Remolina</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Overexpression of the Short Endoglin Isoform Reduces Renal Fibrosis and Inflammation after Unilateral Ureteral Obstruction</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1862</volume>, <fpage>1801</fpage>&#x2013;<lpage>1814</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.06.010</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz-F&#xe9;lix</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Perretta-Tejedor</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Eleno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Salgado</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>ALK1 Heterozygosity Increases Extracellular Matrix Protein Expression, Proliferation and Migration in Fibroblasts</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1843</volume>, <fpage>1111</fpage>&#x2013;<lpage>1122</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.02.017</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munoz-Felix</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Martinez-Salgado</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Dissecting the Involvement of Ras GTPases in Kidney Fibrosis</article-title>. <source>Genes (Basel)</source> <volume>12</volume>, <fpage>800</fpage>, <pub-id pub-id-type="doi">10.3390/genes12060800</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obreo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>D&#xed;ez-Marques</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lamas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D&#xfc;well</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eleno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bernab&#xe9;u</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Endoglin Expression Regulates Basal and TGF-Beta1-Induced Extracellular Matrix Synthesis in Cultured L6E9 Myoblasts</article-title>. <source>Cell Physiol. Biochem.</source> <volume>14</volume>, <fpage>301</fpage>&#x2013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1159/000080340</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Seki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Goss</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Donahoe</surname>
<given-names>P. K.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Activin Receptor-like Kinase 1 Modulates Transforming Growth Factor-Beta 1 Signaling in the Regulation of Angiogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>97</volume>, <fpage>2626</fpage>&#x2013;<lpage>2631</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.97.6.2626</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ouarn&#xe9;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bouvard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boneva</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Desroches-Castan</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>BMP9, but Not BMP10, Acts as a Quiescence Factor on Tumor Growth, Vessel Normalization and Metastasis in a Mouse Model of Breast Cancer</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>37</volume>, <fpage>209</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0885-1</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oujo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz-F&#xe9;lix</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Ar&#xe9;valo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez-G&#xf3;mez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Roque</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pericacho</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>L-endoglin Overexpression Increases Renal Fibrosis after Unilateral Ureteral Obstruction</article-title>. <source>PLoS One</source> <volume>9</volume>, <fpage>e110365</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0110365</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>N. E.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bunclark</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Polwarth</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pepke-Zaba</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Reduced Circulating BMP10 and BMP9 and Elevated Endoglin Are Associated with Disease Severity, Decompensation and Pulmonary Vascular Syndromes in Patients with Cirrhosis</article-title>. <source>EBioMedicine</source> <volume>56</volume>, <fpage>102794</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102794</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pericacho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Llano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Rodr&#xed;guez-Barbero</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Endoglin Haploinsufficiency Promotes Fibroblast Accumulation during Wound Healing through Akt Activation</article-title>. <source>PLoS One</source> <volume>8</volume>, <fpage>e54687</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0054687</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Vogetseder</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaissling</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Le Hir</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Origin of Renal Myofibroblasts in the Model of Unilateral Ureter Obstruction in the Rat</article-title>. <source>Histochem Cell Biol.</source> <volume>130</volume>, <fpage>141</fpage>&#x2013;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1007/s00418-008-0433-8</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodr&#xed;guez-Barbero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Obreo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Alvarez-Munoz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pandiella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernab&#xe9;u</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Endoglin Modulation of TGF-Beta1-Induced Collagen Synthesis Is Dependent on ERK1/2 MAPK Activation</article-title>. <source>Cell Physiol. Biochem.</source> <volume>18</volume>, <fpage>135</fpage>&#x2013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1159/000095181</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodr&#xed;guez-Pe&#xf1;a</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eleno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>D&#xfc;well</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ar&#xe9;valo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Barriocanal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Endoglin Upregulation during Experimental Renal Interstitial Fibrosis in Mice</article-title>. <source>Hypertension</source> <volume>40</volume>, <fpage>713</fpage>&#x2013;<lpage>720</lpage>. <pub-id pub-id-type="doi">10.1161/01.hyp.0000037429.73954.27</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Muragaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Saika</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Ooshima</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Targeted Disruption of TGF-beta1/Smad3 Signaling Protects against Renal Tubulointerstitial Fibrosis Induced by Unilateral Ureteral Obstruction</article-title>. <source>J. Clin. Invest.</source> <volume>112</volume>, <fpage>1486</fpage>&#x2013;<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1172/JCI19270</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharpfenecker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Floot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Korlaar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>ALK1 Heterozygosity Delays Development of Late Normal Tissue Damage in the Irradiated Mouse Kidney</article-title>. <source>Radiother. Oncol.</source> <volume>99</volume>, <fpage>349</fpage>&#x2013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1016/j.radonc.2011.05.061</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharpfenecker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Floot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Coppes</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Endoglin Haploinsufficiency Attenuates Radiation-Induced Deterioration of Kidney Function in Mice</article-title>. <source>Radiother. Oncol.</source> <volume>108</volume>, <fpage>464</fpage>&#x2013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1016/j.radonc.2013.06.016</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharpfenecker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Floot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The TGF-&#x3b2; Co-receptor Endoglin Regulates Macrophage Infiltration and Cytokine Production in the Irradiated Mouse Kidney</article-title>. <source>Radiother. Oncol.</source> <volume>105</volume>, <fpage>313</fpage>&#x2013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1016/j.radonc.2012.08.021</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharpfenecker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Floot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Ten Dijke</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Endoglin Haploinsufficiency Reduces Radiation-Induced Fibrosis and Telangiectasia Formation in Mouse Kidneys</article-title>. <source>Radiother. Oncol.</source> <volume>92</volume>, <fpage>484</fpage>&#x2013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/j.radonc.2009.06.013</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ucero</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Benito-Martin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Izquierdo</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Sanchez-Ni&#xf1;o</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Unilateral Ureteral Obstruction: beyond Obstruction</article-title>. <source>Int. Urol. Nephrol.</source> <volume>46</volume>, <fpage>765</fpage>&#x2013;<lpage>776</lpage>. <pub-id pub-id-type="doi">10.1007/s11255-013-0520-1</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velasco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alvarez-Mu&#xf1;oz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pericacho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dijke</surname>
<given-names>P. T.</given-names>
</name>
<name>
<surname>Bernab&#xe9;u</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Novoa</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>L- and S-Endoglin Differentially Modulate TGFbeta1 Signaling Mediated by ALK1 and ALK5 in L6E9 Myoblasts</article-title>. <source>J. Cell Sci.</source> <volume>121</volume>, <fpage>913</fpage>&#x2013;<lpage>919</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.023283</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viallard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Audiger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Popovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akla</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lanthier</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Legault-Navarrete</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>BMP9 Signaling Promotes the Normalization of Tumor Blood Vessels</article-title>. <source>Oncogene</source> <volume>39</volume>, <fpage>2996</fpage>&#x2013;<lpage>3014</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-020-1200-0</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiercinska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wickert</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Denecke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Said</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Hamzavi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gressner</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Id1 Is a Critical Mediator in TGF-Beta-Induced Transdifferentiation of Rat Hepatic Stellate Cells</article-title>. <source>Hepatology</source> <volume>43</volume>, <fpage>1032</fpage>&#x2013;<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1002/hep.21135</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeisberg</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Potenta</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zeisberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kalluri</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Fibroblasts in Kidney Fibrosis Emerge via Endothelial-To-Mesenchymal Transition</article-title>. <source>J. Am. Soc. Nephrol.</source> <volume>19</volume>, <fpage>2282</fpage>&#x2013;<lpage>2287</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2008050513</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeisberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bottiglio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Maeshima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Strutz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>G. A.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Bone Morphogenic Protein-7 Inhibits Progression of Chronic Renal Fibrosis Associated with Two Genetic Mouse Models</article-title>. <source>Am. J. Physiol. Ren. Physiol.</source> <volume>285</volume>, <fpage>F1060</fpage>&#x2013;<lpage>F1067</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00191.2002</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeisberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kalluri</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Cellular Mechanisms of Tissue Fibrosis. 1. Common and Organ-specific Mechanisms Associated with Tissue Fibrosis</article-title>. <source>Am. J. Physiol. Cell Physiol.</source> <volume>304</volume>, <fpage>C216</fpage>&#x2013;<lpage>C225</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00328.2012</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>